Keywords: reopro, sales, reach, million, eli, lilly, centocor

ReoPro Sales To Reach $240 Million In 1997

Article | 11 December 1997

Print This

Eli Lilly's sales of Centocor's glycoprotein IIb/IIIa inhibitor ReoPro(abciximab) should reach $240 million in 1997, with more growth yet to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in